Диссертация (1139442), страница 54
Текст из файла (страница 54)
30, N 2.– P. 149-155.301. Improvements in benign prostatic hyperplasia-specific quality of life withdutasteride, the novel dual 5alpha-reductase inhibitor / M.P. O'Leary [et al.] // BJUInt. – 2003. – Vol. 92, N 3. – P. 262-266.302. Incidence and prevalence of lower urinary tract symptoms suggestive of benignprostatic hyperplasia in primary care: the Triumph project / К.М. Verhamme [etal.] // Eur.
Urol. – 2002. – Vol. 42. – P. 323-328.303. Individualized Risk Assessment of Prostate Cancer PCPTRC 2.0 [еlectronicresource]. – URL: http://deb.uthscsa.edu/URORiskCalc/Pages/calcs.jsp.304. Inflammation, apoptosis and BPH: what is the evidens? / G. Novara [et al.] // Eur.Urol. – 2006. – Suppl.
5. – P. 401-409.305. Influence of blood prostate specific antigen levels at age 60 on benefits and harmsof prostate cancer screening: population based cohort study [еlectronic resource] /295S.Carlsson[etal.]//BMJ.–2014.–Vol.348.–URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968958.306. Intermediate and longer-term outcomes from a prospective active-surveillanceprogram for favorable-risk prostate cancer / J.J. Tosoian [et al.] // J. Clin.
Oncol. –2015. – N 33. – Р. 3379-3385.307. International variation in prostate cancer incidence and mortality rates / M.M.Center [et al.] // Eur. Urol. – 2012. – Vol. 61, N 6. – P. 1079-1092.308. Jahn J.L. The high prevalence of undiagnosed prostate cancer at autopsy:implications for epidemiology and treatment of prostate cancer in the Prostatespecific Antigen-era [еlectronic resource] / J.L. Jahn, E.L. Giovannucci, M.J.Stampfer//Int.J.Cancer.–2014.–URL:http://www.ncbi.nlm.nih.gov/pubmed/25557753.309. Jain S. Epidemiology of prostate cancer in India / S. Jain, S.
Saxena, A. Kumar //Meta Gene. – 2014. – Vol. 2. – P. 596-605.310. Keto C. A risk-stratified approach to prostate-specific antigen screening / C. Keto,S. Freedland // Eur. Urol. – 2011. – Vol. 59, N 4. – P. 506-508.311. Klotz L. Active surveillance for low-risk prostate cancer] / L.
Klotz // Curr. Urol.Rep.–2015.–Vol.16,N4.–[еlectronicresource].-URL:http://www.ncbi.nlm.nih.gov/pubmed/25764118.312. Knoll T. Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis / T.Knoll // Eur. Urol. – 2010. – Vol. 9. – P. 802-806.313. Kok D.J. Calcium oxalate nephrolithiasis, free or fixed particle disease / D.J. Kok,S.R. Khan // Kidney. Int. – 1994.
– Vol. 46, N 3. – P. 847-854.314. Latent carcinoma of prostate at autopsy in seven areas. The International Agencyfor Research on Cancer, Lyons, France / N. Breslow [et al.] // Int. J. Cancer. –1977. – Vol. 20, N 5. – P. 680-688.315. Lee E.H. Benign prostatic hyperplasia in community-dwelling elderly in Korea /E.H. Lee, K.H. Chun, Y. Lee // Jour. Kor. Acad. Nurs. – 2005.
– Vol. 35, N 8. – P.1508-1513.316. Lee H.L. The prevalence of benign prostatic hyperplasia: community-based studyin Chungbuk province / H.L. Lee, J.W. Seo, W.J. Kim // Korean J. Urol. – 1999. –Vol. 40, N 11. – P. 1500-1505.296317. Logic J.W. Lower urinary tract symptoms suggestive of benign prostaticobstruction: Triumph – the role of general practice data-bases / J.W. Logic, G.M.Clifford G.M., R.D.T. Farmer // Eur. Urol. – 2001.
– Suppl. 3. – P. 42-47.318. Loh A.H. Presentation and progression of benign prostatic hyperplasia: aSingapore experience profiling ethnic differences in a multiracial study cohort /A.H. Loh, K.K. Ng, F.C. Ng // Ann. Acad. Med. Singapore. – 2009. – Vol. 38, N5. – P. 451-456.319. Long-term medical-care costs related to prostate cancer: estimates from linkedSEER-Medicare data / M.E. Stokes [et al.] // Prostate. Cancer. Prostatic. Dis. –2010.
– Vol. 13, N 3. – P. 278-284.320. Lower urinary tract symptoms, prostate volume and uroflow in norwegiancommunity men / G.B. Overland [et al.] // Eur. Urol. – 2001. – Vol. 39, N 1. – P.36-41.321. Magi-Galluzzi C. Contemporary Gleason grading and novel grade groups inclinical practice / С. Magi-Galluzzi, R. Montironi, J.I. Epstein // Curr. Opin. Urol.– 2016. – N 26. – Р. 488-492.322. Magistro G.
New intraprostatic injectables and prostatic urethral lift for maleLUTS / G. Magistro, C.G. Stief, C. Gratzke // Nat. Rev. Urol. – 2015. – № 12. – Р.461-471.323. Male Lower Urinary Tract Symptoms. Evaluation and Management. 6thInternational Consultation on Prostate Cancer and Prostatic Diseases / J. McConnell [et al.]. – Paris, France : Health Publications, 2006. – 401 p.324.
Management of patients with advanced prostate cancer: the report of the AdvancedProstate Cancer Consensus Conference APCCC 2017 / S. Gillessen [et al.] // EurUrol. – 2018. – N 73. – Р. 178-211.325. McDonald R. Alfuzosin for treatment of lower urinary tract symptoms compatiblewith benign prostatic hyperplasia: a systematic review of efficacy and adverseeffects / R. McDonald, T.J.
Wilt // Urology. – 2005. – Vol. 66, N 4. – P. 780-788.326. Mcdonalds C. Standardizing Methodologies for Economic Evaluation in HealthCare / C. Mcdonalds // JAMA. – 1999. – Vol. 282. – P. 1181-1182.327. McNeill S.A. The role of alpha-blockers in the management of acute urinaryretention caused by benign prostatic obstruction / S.A.
McNeill // Eur. Urol. –2004. – Vol. 45, Suppl. 3. – P. 325-332.297328. Moe O.W. Kidney stones: pathophysiology and medical management / O.W. Moe// Lancet. – 2006. – Vol. 367, N 9507. – P. 333-344.329. Nelson W.G. Prostate cancer / W.G. Nelson, A.M. De Marzo, W.B. Isaacs // N.Engl. J. Med. – 2003. – Vol. 349, N 4.
– P. 366-381.330. Outcomes of men with screen-detected prostate cancer eligible for activesurveillance who were managed expectantly / R.C. Van den Bergh [et al.] // Eur.Urol. – 2009. – Vol. 55, N 1. – P. 1-8.331. Parmenter D. Key Performance Indicators: Developing, Implementing and UsingWinning KPI's / D. Parmenter. – New Jersey: John Wiley & Sons, inc., 2007. –233 р.332. Parsons J.K. Benign Prostatic Hyperplasia and Male Lower Urinary TractSymptoms: Epidemiology and Risk Factors / J.K.
Parsons // Curr. BladderDysfunct. Rep. – 2010. – Vol. 5, N 4. – P. 212-218.333. Patel A.R. Risk factors for prostate cancer / A.R. Patel, E.A. Klein // Nat. Clin.Pract. Urol. – 2009. – Vol. 6, N 2. – P. 87-95.334. Pathologic outcomes in favorable-risk prostate cancer: comparative analysis ofmen electing active surveillance and immediate surgery / J.J. Tosoian [et al.] // Eur.Urol. – 2016. – N 69. – Р. 576-581.335. Prediction of indolent prostate cancer: validation and updating of a prognosticnomogram / E.W. Steyerberg [et al.] // J. Urol.
– 2007. – Vol. 177, N 1. – P. 107112.336. Prediction of prostate cancer in unscreened men: external validation of a riskcalculator / H.A. Van Vugt [et al.] // Eur. J. Cancer. – 2011. – Vol. 47, N 6. – P.903-909.337. Prediction of prostate cancer risk: the role of prostate volume and digital rectalexamination in the ERSPC risk calculators / M.J. Roobol [et al.] // Eur. Urol. –2012. – Vol.
61, N 3. – P. 577-583.338. Prevalence of benign prostatic hyperplasia in Jeong-Eup area: community-basedstudy / T.G. Chung [et al.] // Korean J. Urol. – 1999. – Vol. 40, N 1. – P.52-58.339. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older /J.A. Chicharro-Molero [et al.] // J. Urol. – 1998. – Vol. 159. – P. 878-882.298340.
Prevalence of BPH and lower urinary tract symptoms in West Africans / A.P.Chokkalingam [et al.] // Prostate Cancer Prostatic Dis. – 2012. – Vol. 15, N 2. – P.170-176.341. Prevalence of lower urinary tract symptoms related with benign prostatichyperplasia. Study of 1804 men aged 40 or older in Madrid / С. Fernández Pérez[et al.] // Actas. Urol. Esp. – 2009. –Vol. 33, N 1.
– P. 43-51.342. Prevalence of prostate cancer among men with a prostate-specific antigen level≤4.0 ng per milliliter / I.M.Thompson [et al.] // N. Engl. J. Med. – 2004. – N 350. –Р. 2239-2246.343. Prevalence of symptomatic BPE among Malaysian men aged 50 and aboveattending screening during prostate health awareness campaign / G.C. Teh [et al.]// Med. J. Malaysia. – 2001. – Vol.
56, N 2. – P. 186-195.344. Prevention and early detection of prostate cancer / J. Cuzick [et al.] // LancetOncol. – 2014. – Vol. 15, N 11. – P. 484-492.345. Prospective multi-institutional study evaluating the performance of prostate cancerrisk calculators / R.K. Nam [et al.] // J. Clin. Oncol. – 2011. – Vol. 29, N 22. – P.2959-2964.346.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
